|
1
|
Sipos W, Pietschmann P, Rauner M,
Kerschan-Schindl K and Patsch J: Pathophysiology of osteoporosis.
Wien Med Wochenschr. 159:230–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weitzmann MN and Pacifici R: Estrogen
deficiency and bone loss: An inflammatory tale. J Clin Invest.
116:1186–1194. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rachner TD, Khosla S and Hofbauer LC:
Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhai YK, Pan YL, Niu YB, Li CR, Wu XL, Fan
WT, Lu TL, Mei QB and Xian CJ: The importance of the prenyl group
in the activities of osthole in enhancing bone formation and
inhibiting bone resorption in vitro. Int J Endocrinol.
2014:9219542014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yogesh HS, Chandrashekhar VM, Katti HR,
Ganapaty S, Raghavendra HL, Gowda GK and Goplakhrishna B:
Anti-osteoporotic activity of aqueous-methanol extract of Berberis
aristata in ovariectomized rats. J Ethnopharmacol. 134:334–338.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee WS, Lee EG, Sung MS and Yoo WH:
Kaempferol inhibits IL-1β-stimulated, RANKL-mediated
osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1.
Inflammation. 37:1221–1230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tyagi AM, Srivastava K, Singh AK, Kumar A,
Changkija B, Pandey R, Lahiri S, Nagar GK, Yadav DK, Maurya R, et
al: Formononetin reverses established osteopenia in adult
ovariectomized rats. Menopause. 19:856–863. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H,
Ouyang Z, Xu X, Wang W, Fan Q, et al: The effect of enoxacin on
osteoclastogenesis and reduction of titanium particle-induced
osteolysis via suppression of JNK signaling pathway. Biomaterials.
35:5721–5730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ouyang Z, Zhai Z, Li H, Liu X, Qu X, Li X,
Fan Q, Tang T, Qin A and Dai K: Hypericin suppresses osteoclast
formation and wear particle-induced osteolysis via modulating ERK
signalling pathway. Biochem Pharmacol. 90:276–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Zhai Z, Liu G, Tang T, Lin Z, Zheng
M, Qin A and Dai K: Sanguinarine inhibits osteoclast formation and
bone resorption via suppressing RANKL-induced activation of NF-κB
and ERK signaling pathways. Biochem Biophys Res Commun.
430:951–956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qu X, Zhai Z, Liu X, Li H, Ouyang Z, Wu C,
Liu G, Fan Q, Tang T, Qin A and Dai K: Dioscin inhibits osteoclast
differentiation and bone resorption though down-regulating the Akt
signaling cascades. Biochem Biophys Res Commun. 443:658–665. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mackraj I, Govender T and Gathiram P:
Sanguinarine. Cardiovasc Ther. 26:75–83. 2008.PubMed/NCBI
|
|
13
|
American Psychological Association:
Guidelines for Ethical Conduct in the Care and Use of Nonhuman
Animals in Research. Washington, DC: American Psychological
Association; 2012, http://www.apa.org/science/leadership/care/guidelines.aspx
|
|
14
|
Thompson DD, Simmons HA, Pirie CM and Ke
HZ: FDA Guidelines and animal models for osteoporosis. Bone.
17:125S–133S. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bouxsein ML, Boyd SK, Christiansen BA,
Guldberg RE, Jepsen KJ and Muller R: Guidelines for assessment of
bone microstructure in rodents using micro-computed tomography. J
Bone Miner Res. 25:1468–1486. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Das S and Crockett JC: Osteoporosis-a
current view of pharmacological prevention and treatment. Drug Des
Devel Ther. 7:435–448. 2013.PubMed/NCBI
|
|
18
|
Buck DW III and Dumanian GA: Bone biology
and physiology: Part I. The fundamentals. Plast Reconstr Surg.
129:1314–1320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Odvina CV, Zerwekh JE, Rao DS, Maalouf N,
Gottschalk FA and Pak CY: Severely suppressed bone turnover: A
potential complication of alendronate therapy. J Clin Endocrinol
Metab. 90:1294–1301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaidi M and Iqbal J: Translational
medicine: Double protection for weakened bones. Nature. 485:47–48.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng
G and Hu J: The effects of combined human parathyroid hormone
(1–34) and zoledronic acid treatment on fracture healing in
osteoporotic rats. Osteoporos Int. 23:1463–1474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bonnelye E, Chabadel A, Saltel F and
Jurdic P: Dual effect of strontium ranelate: Stimulation of
osteoblast differentiation and inhibition of osteoclast formation
and resorption in vitro. Bone. 42:129–138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu LL, Blair H, Cao J, Yuen T, Latif R,
Guo L, Tourkova IL, Li J, Davies TF, Sun L, et al: Blocking
antibody to the β-subunit of FSH prevents bone loss by inhibiting
bone resorption and stimulating bone synthesis. Proc Natl Acad Sci
USA. 109:14574–14579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smoum R, Bar A, Tan B, Milman G,
Attar-Namdar M, Ofek O, Stuart JM, Bajayo A, Tam J, Kram V, et al:
Oleoyl serine, an endogenous N-acyl amide, modulates bone
remodeling and mass. Proc Natl Acad Sci USA. 107:17710–17715. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hayashi M, Nakashima T, Taniguchi M,
Kodama T, Kumanogoh A and Takayanagi H: Osteoprotection by
semaphorin 3A. Nature. 485:69–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
